Pharma consultancy Boyds enhances clinical, medical affairs services

By Melissa Fassbender contact

- Last updated on GMT

(Image: Kritchanut)
(Image: Kritchanut)

Related tags: Medical affairs, regulatory

The pharmaceutical and biotech product development consultancy Boyds acquires Blue Duck Consulting to boost its clinical and medical affairs services offering.

Blue Duck provides preclinical and clinical drug development support, including specialist monitoring and clinical operations project management, according to the company.

Blue Duck’s clinical monitoring services will fall under Boyds’ regulatory and medical monitoring support services umbrella, “to strengthen its ability to identify and develop therapies that will benefit patients,”​ said Boyds CEO Alan Boyd in a statement.

“In addition to the regulatory, medical monitoring and product development services already offered by Boyds, our clients will now also be able to seamlessly access clinical development services which include study set-up activities, from feasibility assessments and ethics submissions, to site contract negotiations, clinical study monitoring, and clinical study project management,”​ he added.

Following the transaction, Blue Duck founder Dr. Karen O’Hanlon is now the director of clinical operations at Boyds.

Said Boyds, the company will “continue to build on the monitoring provision that Blue Duck has already built up in the UK, Europe, USA, Mexico and Canada.”

Boyds also earlier this year opened a new office​ in Dublin, Ireland, which the CEO told us at the time will serve as “a bit of an insurance policy”​ ahead of Brexit.

Related news

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more